Recent developments of HDAC inhibitors: Emerging indications and novel molecules

The histone deacetylase enzymes, a class of epigenetic regulators, are historically well‐established as attractive therapeutic targets. In this review, the authors provide an overview of clinical drug development and analysis of specific trials, and highlight recent advances.

Source:

British Journal of Clinical Pharmacology